Summary by Futu AI
Thomas A. Fitzgerald, the Interim CEO, CFO, and a board member of TransCode Therapeutics, Inc., filed a Schedule 13D with the SEC on June 21, 2024, indicating a significant ownership stake in the company. Fitzgerald reported beneficial ownership of 422,036 shares of TransCode Therapeutics' common stock, which represents approximately 5.5% of the company's outstanding shares. This stake includes 1,408 shares held directly and 420,628 shares issuable upon the exercise of stock options within 60 days of the filing date. The filing, which details Fitzgerald's potential influence over corporate activities, also notes his right to acquire additional shares or dispose of his holdings in the future. Fitzgerald's investment decisions are expected to be influenced by a variety of factors, including the company's business prospects and market conditions.